Mark A. Glickman's most recent trade in MetaVia Inc. was a trade of 28,147 Common Stock done . Disclosure was reported to the exchange on June 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| MetaVia Inc. | Mark A. Glickman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 28,147 | 37,887 (0%) | 0% | 0 | Common Stock | |
| MetaVia Inc. | Mark A. Glickman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 5,051 | 9,740 (0%) | 0% | 0 | Common Stock | |
| MetaVia Inc. | Mark A. Glickman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jul 2023 | 25,000 | 25,000 (0%) | 0% | 0 | Common Stock | |
| MetaVia Inc. | Mark A. Glickman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jul 2023 | 12,500 | 37,500 (0%) | 0% | 0 | Common Stock | |
| TherapeuticsMD Inc | Mark A. Glickman | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 260,000 | 260,000 | - | - | Performance Stock Units | |
| TherapeuticsMD Inc | Mark A. Glickman | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Mar 2022 | 260,000 | 260,000 | - | - | Restricted Stock Units |